IPF and Health Care Policy: Values of Patients and Society

Cardiovascular Co-Morbidities in IPF Patients May Worsen Prognosis

Patients with idiopathic pulmonary fibrosis (IPF) often exhibit cardiovascular manifestations that affect patients’ morbidity and mortality according to the study”Cardiac manifestations of idiopathic pulmonary fibrosis,” published in Intractable and Rare Diseases Research. The authors reviewed evidence that links cardiovascular diseases to IPF and how the co-morbidities…

What is Idiopathic Pulmonary Fibrosis?

What is idiopathic pulmonary fibrosis (IPF)? IPF is a rare lung disease in which tissue deep in your lungs becomes thick and stiff, or scarred, over time. This scarring of the lung tissue causes IPF patients to experience severe difficulties in breathing among other serious symptoms. In this animated…

Fibrotic Disease Therapy Research Collaboration Established Between Boehringer Ingelheim, Harvard Scientists

The Germany-based global pharmaceutical company Boehringer Ingelheim recently announced the establishment of a research alliance with the Harvard Stem Cell Institute (HSCI) to discover new targets for treating fibrotic diseases, such as chronic kidney disease (CKD), nonalcoholic steatohepatitis (NASH), and idiopathic pulmonary fibrosis (IPF). The collaborative project, called Harvard Fibrosis Network, is…

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums